FDA grants priority review to Opdivo for gastric, esophageal cancer indications

The FDA granted priority review to nivolumab for two gastrointestinal cancer indications, according to the agent’s manufacturer.One designation applies to use of the agent with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.The other designation applies to use of the drug as adjuvant therapy for patients with resected esophageal or gastroesophageal junction cancer.Nivolumab (Opdivo, Bristol Myers Squibb) is an anti-PD-1 antibody.The FDA based the priority reviewRead More

Share on facebook
Share on twitter
Share on linkedin